Some GnRH agonists are also used in women to help manage the pain caused by endometriosis, to improve anemia associated with uterine fibroids prior to hysterectomy and in some cases for palliative treatment of advanced breast cancer. Use of these products should not exceed one year for women except in treating breast cancer. There are no known comparable studies that have evaluated the risk of diabetes and heart disease in women taking GnRH agonists.

Some GnRH agonists are also used in children to treat central precocious puberty. There are no known studies that have evaluated the risk of diabetes and heart disease in children taking GnRH agonists.

Eligard is marketed by Bridgewater, N.J.-based Sanofi-Aventis.Lupron is marketed by Abbott Park, Ill.-based Abbott Laboratories.Synarel is marketed by New York City-based Pfizer.Trelstar is marketed by Corona, Calif.-based Watson Pharmaceuticals.Vantas is marketed by Chadds Ford, Pa.-based Endo Pharmaceuticals.Viadur is marketed by Wayne, N.J.-based Bayer Pharmaceuticals.Zoladex is marketed by Wilmington, Del.-based AstraZeneca.

 For more information:

Drug Safety Communication: Ongoing Safety Review of GnRH Agonists and Possible Increased Risk of Diabetes and Certain Cardiovascular Diseases FDA Office of Oncology Drug Productsfda